Kwality Pharmaceuticals Ltd. (KPL) Share Price Rises 12.91% Today

Kwality Pharmaceuticals Ltd. share price today stood at Rs 2945.75, up 12.91%. The company’s market capitalisation was Rs 2,707.20 crore during this small-cap top-gainer move.

Kwality Pharmaceuticals Ltd. Share Price moved sharply higher on 10 August 2026, with the stock trading at Rs 2945.75, up Rs 336.70 or 12.91% from the previous close of Rs 2609.05. With a market capitalisation of Rs 2,707.20 crore, the company entered the day’s market conversation as a notable small-cap top gainer in the Healthcare space. The move matters because it was not a marginal uptick: the stock opened at Rs 2662.20, traded as low as Rs 2558.70 and then climbed to an intraday high of Rs 2949.90.

For readers tracking Kwality Pharmaceuticals Ltd. Share Price Today, the supplied data confirms a significant same-day price rise and strong intraday recovery, but it does not establish a company-specific catalyst behind the move. That distinction matters in Stock Market Today coverage because price action can sometimes become the main verified story before any separate company announcement is evident in the dataset.

Kwality Pharmaceuticals Ltd. Stock News is also drawing attention because turnover reached Rs 2.10 crore and total traded volume stood at 1,09,255 shares across exchanges. On BSE, volume was 7,112 shares, while NSE volume was 1,02,143 shares. For investors following Share Market Today and Stocks in News, Univest notes that the stock’s rise combines strong daily momentum with a valuation and profitability profile that deserves closer inspection rather than a headline-only reading.

Kwality Pharmaceuticals Ltd. (KPL) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,945.75
Previous Close	Rs 2,609.05
Today's Change	+Rs 336.7 (+12.91%)
Day Open	Rs 2,662.2
Day High	Rs 2,949.9
Day Low	Rs 2,558.7
Current Volume (BSE)	7,112
BSE Traded Volume	7,112
NSE Traded Volume	1,02,143
Combined NSE + BSE Volume	1,09,255
Turnover	Rs 2.1 crore
Market Capitalisation	Rs 2,707.2 crore
Market Cap Category	Small Cap

Kwality Pharmaceuticals Ltd. (KPL) traded at Rs 2,945.75. versus the previous close of Rs 2,609.05, a rise of 12.91%. The stock opened at Rs 2,662.2, reached Rs 2,949.9, touched Rs 2,558.7. Reported volume was 7,112.

Kwality Pharmaceuticals Ltd. (KPL) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 2,707.2 crore
P/E Ratio	40.2x
P/B Ratio	8.18x
ROE	28.21%
ROCE	26.35%
EPS	Rs 64.9
Dividend Yield	0%

Kwality Pharmaceuticals Ltd. was valued at a P/E ratio of 40.2x, a P/B ratio of 8.18x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 28.21% and ROCE of 26.35%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 64.9, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Kwality Pharmaceuticals Ltd. Fundamental Analysis begins with size and valuation. The company’s market capitalisation stands at Rs 2,707.20 crore, which places it in the small-cap bracket but still makes it larger than many listed names in its industry universe. Its P/E ratio is 40.20 and its P/B ratio is 8.18. Those are not standalone conclusions, but they immediately signal that the market is assigning a meaningful valuation to the company relative to its reported earnings and net worth.

Profitability metrics are notably stronger than what many small-cap screens alone would suggest. Return on equity is 28.21%, while return on capital employed is 26.35%. Both figures indicate that the business has been generating robust returns on shareholder equity and on capital employed. In Stock Analysis terms, that helps explain why investor attention may persist even when the share price becomes more demanding on valuation multiples.

EPS is Rs 64.90, which shows the earnings attributable to each share on the supplied basis. Dividend yield is 0, meaning the current data does not reflect a cash yield component in the stock’s present profile. That pushes the market conversation more toward earnings power, profitability ratios and price behaviour rather than income distribution. Because the stock price is Rs 2945.75 and EPS is Rs 64.90, the resulting P/E of 40.20 aligns with the supplied valuation figure and reinforces that the market is capitalising the company at a premium to many traditional manufacturing-style businesses.

The P/B ratio of 8.18 is also a key marker in any Kwality Pharmaceuticals Ltd. Share Price Update. A higher price-to-book multiple generally indicates that the market values the company well above accounting net worth, often because of profitability expectations, business quality, or scarcity value within a niche segment. Univest would therefore frame the current setup as one where profitability is strong on the supplied data, while valuation requires context from the broader Pharmaceuticals & Drugs industry rather than a simple cheap-or-expensive label. That bridge matters before moving to sector and peer comparison.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	40.2x
Benchmark Median P/E	26.3x
Benchmark Average P/E	80.76x
Benchmark P/E Range	3.21x to 3,417.8x
Company P/B Ratio	8.18x
Benchmark Median P/B	1.83x
Company ROE	28.21%
Benchmark Median ROE	9.93%
Company ROCE	26.35%
Benchmark Median ROCE	12.96%
Company Market Capitalisation	Rs 2,707.2 crore
Benchmark Median Market Cap	Rs 142.44 crore

Kwality Pharmaceuticals Ltd. (KPL) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Kwality Pharmaceuticals Ltd. (KPL) has a P/E ratio of 40.2x, which is above the benchmark median of 26.3x, a difference of +52.85%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Kwality Pharmaceuticals Ltd. (KPL) has a ROE of 28.21%, which is above the benchmark median of 9.93%, a difference of +184.09%. Kwality Pharmaceuticals Ltd. (KPL) has a ROCE of 26.35%, which is above the benchmark median of 12.96%, a difference of +103.32%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Kwality Pharmaceuticals Ltd. operates in Healthcare, specifically in Pharmaceuticals & Drugs, and the benchmark used here covers the same industry with 140 companies. That scope is useful because it allows the stock’s valuation and profitability to be compared with businesses facing a more similar industry setting rather than with the wider Indian Stock Market.

The company P/E is 40.20. Within the benchmark, P/E data is available for 104 companies, with a median of 26.30, an average of 80.76, a minimum of 3.21 and a maximum of 3417.80. This places Kwality Pharmaceuticals Ltd. above the industry median but below the industry average. In other words, the stock is not priced near the most extreme valuation points in the sector set, but it is still trading richer than the median company on earnings multiple.

The P/B comparison is even more striking. Kwality Pharmaceuticals Ltd. has a P/B of 8.18, versus an industry median of 1.83 and average of 2.92 across 139 companies, with a range from -16 to 59.75. On this metric, the stock clearly sits above both the median and average benchmark figures. That means investors following Kwality Pharmaceuticals Ltd. Share Price Rise should recognise that the market is assigning a substantial premium to its book value relative to much of the same-industry basket.

Profitability, however, is stronger than the benchmark. ROE is 28.21% versus an industry median of 9.93% and average of 7.45% across 139 companies. ROCE is 26.35% versus a median of 12.96% and average of 14.33%. Those differences matter because they show the company’s return metrics are materially ahead of broad industry central tendencies. The market-cap context also stands out: at Rs 2,707.20 crore, the company is far above the industry median market capitalisation of Rs 142.44 crore and above the average of Rs 489.44 crore, though still below the industry maximum of Rs 3,032.97 crore. Univest reads this as a stock with premium valuation signals but also clearly stronger profitability than many sector counterparts.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,032.97	31.12	0.45	-2.89	-0.26
Hikal Ltd.	HIKAL	2,799.54	0	2.35	15.22	16.15
Beta Drugs Ltd.	BETA	2,631.45	63.43	6.27	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,531.49	0	3.03	0	5.36
Sai Parenteral's Ltd.	SAIPARENT	2,513.58	176.28	3.26	13.9	12.97

Kwality Pharmaceuticals Ltd. (KPL) has a P/E ratio of 40.2x compared with the displayed peer median of 31.12x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 28.21% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at 26.35% versus the displayed peer median of 12.97%, providing a capital-efficiency comparison. Kwality Pharmaceuticals Ltd. (KPL) has a market capitalisation of Rs 2,707.2 crore. Among the 5 peers shown, 2 have a larger market capitalisation.

Peer data gives a sharper view of how Kwality Pharmaceuticals Ltd. Share Price is being valued against similarly sized listed names in Pharmaceuticals & Drugs. At a market cap of Rs 2,707.20 crore, the company sits close to Hikal Ltd. at Rs 2,799.54 crore and Beta Drugs Ltd. at Rs 2,631.45 crore, while remaining below Dishman Carbogen Amcis Ltd. at Rs 3,032.97 crore. This puts Kwality Pharmaceuticals in a fairly comparable market-cap cluster rather than in an outlier size bucket.

On valuation, Kwality Pharmaceuticals’ P/E of 40.20 is higher than Dishman Carbogen Amcis at 31.12 and lower than Beta Drugs at 63.43, NGL Fine-Chem at 44.02 and Sai Parenteral’s at 176.28. Venus Remedies trades at 17.81 and Hester Biosciences at 15.11, both clearly below Kwality’s multiple. That suggests the stock is neither the cheapest nor the most aggressively valued name in the peer subset, but it is still trading at a premium to several peers.

The profitability comparison is constructive. ROE at 28.21% is above Beta Drugs at 18.65%, Hikal at 15.22%, Sai Parenteral’s at 13.90%, Solara Active Pharma Sciences at 17.23%, Venus Remedies at 9.85% and Hester Biosciences at 16.17%. It is also above NGL Fine-Chem’s 27.90% by a narrow margin and far ahead of Dishman Carbogen Amcis at -2.89% and Panacea Biotec at 0. ROCE at 26.35% is stronger than most peers as well, though it trails NGL Fine-Chem’s 33.91%.

P/B of 8.18 is above Beta Drugs at 6.27, NGL Fine-Chem at 6.43, Hester Biosciences at 4.52, Sai Parenteral’s at 3.26, Panacea Biotec at 3.03, Venus Remedies at 3.01, Hikal at 2.35, Solara at 1.90 and Dishman at 0.45. That means the stock commands one of the highest book-value multiples in the peer set. The overall picture from Univest is clear: relative profitability is strong, but the valuation premium is also visible when judged against comparable listed pharma names.

Why Investors Are Watching Kwality Pharmaceuticals Ltd.

Investors are watching Kwality Pharmaceuticals Ltd. Share Price because today’s move combines sharp price action, a small-cap event qualification, healthy profitability ratios and a clear premium valuation profile. In Market News terms, this is the type of setup that attracts attention from both momentum-focused traders and fundamentally oriented investors who want to understand whether strong returns on capital are being reflected in the stock price.

• Verified price action: the stock rose 12.91% to Rs 2945.75 from Rs 2609.05, with an intraday range between Rs 2558.70 and Rs 2949.90.
• Trading activity: total volume reached 1,09,255 shares, including 7,112 on BSE and 1,02,143 on NSE, with turnover of Rs 2.10 crore.
• Fundamental context: P/E is 40.20, P/B is 8.18, ROE is 28.21%, ROCE is 26.35% and EPS is Rs 64.90.
• Sector positioning: profitability metrics sit above industry medians, while valuation multiples also trade above broad benchmark central levels.
• Peer positioning: the stock compares favourably on ROE and ROCE versus many peers, but not on book-value multiple.

What should investors monitor next? The most immediate points are whether Kwality Pharmaceuticals Ltd. Share Price can hold near today’s higher levels, whether trading activity remains elevated, and how the valuation premium continues to compare with peers in Pharmaceuticals & Drugs. Univest would also watch whether the market keeps rewarding the company’s stronger profitability profile relative to the same-industry benchmark.

About Kwality Pharmaceuticals Ltd.

Kwality Pharmaceuticals Ltd. is classified in the Healthcare sector and Pharmaceuticals & Drugs industry. Even without an extended business description in the supplied dataset, that classification alone places the company within one of the most tracked corners of the Indian stock market because pharmaceutical businesses are commonly evaluated through earnings quality, return ratios, valuation multiples and market-cap positioning.

Within its industry benchmark, Kwality Pharmaceuticals stands out by size as well as profitability. Its market capitalisation of Rs 2,707.20 crore is substantially higher than the benchmark median of Rs 142.44 crore and the average of Rs 489.44 crore across 140 same-industry companies. That indicates the company is not a fringe micro player inside the listed Pharmaceuticals & Drugs universe.

The stock’s reported return profile is also notable in company context. ROE of 28.21% and ROCE of 26.35% both sit ahead of industry medians, which helps explain why the stock may command closer investor attention in a busy Healthcare screen. At the same time, P/E of 40.20 and P/B of 8.18 show that the market is not pricing the company like a deep-value outlier. For readers searching Kwality Pharmaceuticals Ltd. Company News, the verified takeaway is that this is a listed pharma name whose share price behaviour is being read through the lens of strong reported profitability and a premium market valuation within its industry cohort.

Track Kwality Pharmaceuticals Ltd. Share Price on Univest

Use Kwality Pharmaceuticals Ltd. (KPL) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Readers who want to follow Kwality Pharmaceuticals Ltd. Share Price more closely can track the stock on Univest for live price movement, daily change, market capitalisation and broader stock analysis context. Univest also helps users monitor valuation ratios such as P/E and P/B, profitability measures including ROE and ROCE, and market-reference indicators such as 52-week levels when available in the platform dataset.

For investors comparing Healthcare names, Univest is useful not just for Kwality Pharmaceuticals Ltd. Share Price Today but also for peer comparison, sector benchmark context, shareholding pattern updates when reported, and ongoing market insights. In a session where the stock is part of Stocks in News and Top Gainers Today discussions, organised tracking can matter more than reacting to a single headline.

Frequently Asked Questions

Why is Kwality Pharmaceuticals Ltd. share price rising today?

Ans. Kwality Pharmaceuticals Ltd. share price rose 12.91% today to Rs 2945.75 from the previous close of Rs 2609.05. The supplied data confirms the price event and trading activity, but it does not establish a company-specific catalyst.

What is Kwality Pharmaceuticals Ltd. Share Price Today?

Ans. Kwality Pharmaceuticals Ltd. Share Price Today was Rs 2945.75 at the time of the dataset. That represented a gain of Rs 336.70 or 12.91% over the previous close of Rs 2609.05 in today’s session.

What was the intraday range for Kwality Pharmaceuticals Ltd. today?

Ans. The stock opened at Rs 2662.20, touched an intraday low of Rs 2558.70 and climbed to a high of Rs 2949.90. This wide range shows a volatile session that eventually resolved with a strong positive close-level move.

What is the market capitalisation of Kwality Pharmaceuticals Ltd.?

Ans. The company’s market capitalisation was Rs 2,707.20 crore in the supplied data. That places Kwality Pharmaceuticals Ltd. in the small-cap category, while still making it larger than the industry median market cap of Rs 142.44 crore.

How much volume was traded in Kwality Pharmaceuticals Ltd. shares today?

Ans. Total traded volume was 1,09,255 shares. Of this, 7,112 shares were on BSE and 1,02,143 shares were on NSE, while reported turnover stood at Rs 2.10 crore during the session.

Is Kwality Pharmaceuticals Ltd. expensive based on P/E and P/B?

Ans. Kwality Pharmaceuticals Ltd. trades at a P/E of 40.20 versus the industry median of 26.30, and a P/B of 8.18 versus the industry median of 1.83. On both measures, the stock is above benchmark median levels.

How profitable is Kwality Pharmaceuticals Ltd. compared with its industry?

Ans. The company’s ROE is 28.21% and ROCE is 26.35%. Both are higher than the same-industry medians of 9.93% and 12.96%, indicating stronger reported profitability than broad benchmark central levels. The stock belongs to the Healthcare sector.

What does EPS and dividend yield show for Kwality Pharmaceuticals Ltd.?

Ans. EPS is Rs 64.90, showing the earnings attributable to each share on the supplied basis. Dividend yield is 0, so the present data points more toward earnings and valuation discussion than cash-yield support.

How does Kwality Pharmaceuticals Ltd. compare with peers?

Ans. Kwality Pharmaceuticals Ltd. has a market cap of Rs 2,707.20 crore, close to peers such as Hikal and Beta Drugs. Its ROE of 28.21% is stronger than many peers, but its P/B of 8.18 is also higher.

What should investors monitor after today’s move in Kwality Pharmaceuticals Ltd.?

Ans. Investors may track whether the stock holds near Rs 2945.75 after today’s 12.91% rise, how trading volumes evolve, and whether valuation metrics continue to look justified relative to peer and industry profitability data.